DNAY Stock Performance, Insider Transaction and News

DNAY - Codex DNA, Inc.

Market Cap	38.38M	P/E	-	EPS this Y	14.50%	Ern Qtrly Grth	-
Income	-52.83M	Forward P/E	-0.85	EPS next Y	16.40%	50D Avg Chg	-7.00%
Sales	21.04M	PEG	-	EPS past 5Y	-	200D Avg Chg	-45.00%
Dividend	N/A	Price/Book	0.72	EPS next 5Y	-	52W High Chg	-88.00%
Recommedations	1.70	Quick Ratio	4.33	Shares Outstanding	29.52M	52W Low Chg	20.00%
Insider Own	37.14%	ROA	-29.63%	Shares Float	7.53M	Beta	-
Inst Own	43.64%	ROE	-67.70%	Shares Shorted/Prior	133.25K/325.67K	Price	1.30
Gross Margin	47.67%	Profit Margin	-251.05%	Avg. Volume	79,397	Target Price	6.50
Oper. Margin	-239.49%	Earnings Date	Nov 8	Volume	19,945	Change	8.33%

Healthcare | Medical Devices | United States

About Codex DNA, Inc.

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

DNAY Chatroom

VertanosTrading Posted - 2 months ago

$DNAY why is this 130% up? 😂

VertanosTrading Posted - 2 months ago

$DNAY why is this up 30%?

cctranscripts Posted - 4 months ago

Codex DNA, Inc.'s Chief Financial Officer was just granted 300,000 options https://www.conferencecalltranscripts.org/summary/?id=12766670 $DNAY

cctranscripts Posted - 4 months ago

Codex DNA, Inc.'s Chief Financial Officer just declared ownership of no shares of Codex DNA, In https://www.conferencecalltranscripts.org/summary/?id=12766641 $DNAY

cctranscripts Posted - 5 months ago

Entry into a Material Definitive https://www.conferencecalltranscripts.org/summary/?id=12753933 $DNAY

cctranscripts Posted - 5 months ago

Codex DNA, Inc. Just Filed Its Quarterly Report: 15.NET LOSS PER SHAR... https://www.conferencecalltranscripts.org/summary/?id=12702143 $DNAY

cctranscripts Posted - 5 months ago

Codex DNA: Telesis Bio Reports Third Quarter 2023 Financial Results https://www.conferencecalltranscripts.org/summary/?id=12702112 $DNAY

EarningsInsider Posted - 5 months ago

Telesis Bio, Inc. Files SEC Form 10-Q $DNAY https://www.marketbeat.com/stocks/NASDAQ/DNAY/sec-filings/

EarningsInsider Posted - 5 months ago

Telesis Bio, Inc. Files SEC Form 8-K $DNAY https://www.marketbeat.com/stocks/NASDAQ/DNAY/sec-filings/

risenhoover Posted - 5 months ago

$DNAY / Codex DNA files form 10-Q https://fintel.io/doc/sec-telesis-bio-inc-1850079-10q-2023-november-13-19674-594?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

risenhoover Posted - 5 months ago

$DNAY / Codex DNA files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 https://fintel.io/doc/sec-telesis-bio-inc-1850079-8k-2023-november-13-19674-9861?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

cctranscripts Posted - 5 months ago

Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation u https://www.conferencecalltranscripts.org/summary/?id=12694027 $DNAY

EarningsInsider Posted - 5 months ago

Telesis Bio, Inc. Files SEC Form 8-K $DNAY https://www.marketbeat.com/stocks/NASDAQ/DNAY/sec-filings/

cctranscripts Posted - 6 months ago

Codex DNA, Inc. director just declared ownership of no shares of Codex DNA, Inc. https://www.conferencecalltranscripts.org/summary/?id=12639620 $DNAY

cctranscripts Posted - 6 months ago

Codex DNA, Inc. director just picked up 153,191 shares https://www.conferencecalltranscripts.org/summary/?id=12639618 $DNAY

cctranscripts Posted - 6 months ago

Departure of Directors or Certain https://www.conferencecalltranscripts.org/summary/?id=12636695 $DNAY

cctranscripts Posted - 7 months ago

Departure of Directors or Certain https://www.conferencecalltranscripts.org/summary/?id=12561397 $DNAY

Quantisnow Posted - 7 months ago

$DNAY 📜 Codex DNA Inc. filed SEC Form 8-K: Leadership Update https://quantisnow.com/i/4984909?utm_source=stocktwits 45 seconds delayed.

macroaxis Posted - 7 months ago

$DNAY - Symbol renaming can cause some disturbance for Codex DNA https://www.macroaxis.com/predict/DNAY/Codex-DNA #stocks #earnings

cctranscripts Posted - 8 months ago

Codex DNA: Telesis Bio Appoints William J. Kullback Chief Financial Officer https://www.conferencecalltranscripts.org/summary/?id=12496089 $DNAY

macroaxis Posted - 8 months ago

$DNAY - Enters -0.0418 Risk Adjusted Performance. Symbol was renamed to TBIO on 4th of January 2023 https://www.macroaxis.com/invest/technicalIndicator/DNAY/Risk-Adjusted-Performance #stocks #earnings

cctranscripts Posted - 8 months ago

Codex DNA, Inc. Just Filed Its Quarterly Report: 15.NET LOSS PER SHAR... https://www.conferencecalltranscripts.org/summary/?id=12446474 $DNAY

risenhoover Posted - 8 months ago

$DNAY / Codex DNA files form 10-Q https://fintel.io/sf/us/dnay?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

Quantisnow Posted - 8 months ago

$DNAY 📜 SEC Form 10-Q filed by Codex DNA Inc. https://quantisnow.com/i/4881354?utm_source=stocktwits 45 seconds delayed.

cctranscripts Posted - 8 months ago

Codex DNA: Telesis Bio Reports Second Quarter 2023 Financial Results https://www.conferencecalltranscripts.org/summary/?id=12443534 $DNAY

risenhoover Posted - 8 months ago

$DNAY / Codex DNA files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 https://fintel.io/sf/us/dnay?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

Quantisnow Posted - 8 months ago

$DNAY 📜 Codex DNA Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits https://quantisnow.com/i/4879160?utm_source=stocktwits 45 seconds delayed.

cctranscripts Posted - 8 months ago

Notice of Effectiveness https://www.conferencecalltranscripts.org/summary/?id=12421250 $DNAY

Quantisnow Posted - 8 months ago

$DNAY 📜 SEC Form EFFECT filed by Codex DNA Inc. https://quantisnow.com/i/4846266?utm_source=stocktwits 45 seconds delayed.

risenhoover Posted - 9 months ago

$DNAY / Codex DNA files form S-3 https://fintel.io/sf/us/dnay?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

Analyst Ratings

Keybanc	Overweight	Nov 9, 22
Keybanc	Overweight	Mar 28, 22
Jefferies	Buy	Jul 13, 21
Cowen & Co.	Outperform	Jul 13, 21
Keybanc	Overweight	Jul 13, 21